RESUMO
This chapter first summarizes the therapy of addiction disorder, and elaborates on the progress of medication. First, the difference between dependency and addiction are introduced. The basic principles of the therapy of substance and non-substance addiction are then put forward. It is also pointed out in this chapter that with the progress of the study, the goal of addiction disorder therapy is expected to transfer from reducing the relapse and harm of the addiction to completely eliminating and recovering from it. This chapter also introduces the progress of psychological addiction elimination technology, especially the "Unconditioned Stimulus Retrieval Extinction Paradigm and Conditioned Stimulus Retrieval Extinction Paradigm" and PITDH technology. Finally it is pointed out that in addiction disorder therapy, comprehensive intervention has become a trend. With regard to the medication for addiction disorders, this chapter also includes the progress and deficiencies of substance and non-substance addiction. In terms of addiction disorder rehabilitation, the foundation of substance addiction is medication which is, however, limited for non-substance addiction. The key to the rehabilitation of addiction disorder is psycho-behavioral therapy, which is especially effective in eliminating craving.
Assuntos
Comportamento Aditivo/tratamento farmacológico , Encéfalo/efeitos dos fármacos , Fármacos do Sistema Nervoso Central/uso terapêutico , Usuários de Drogas/psicologia , Transtornos Relacionados ao Uso de Substâncias/tratamento farmacológico , Atitude Frente aos Computadores , Comportamento Aditivo/diagnóstico , Comportamento Aditivo/fisiopatologia , Comportamento Aditivo/psicologia , Encéfalo/fisiopatologia , Fármacos do Sistema Nervoso Central/efeitos adversos , Dependência de Alimentos/tratamento farmacológico , Dependência de Alimentos/fisiopatologia , Dependência de Alimentos/psicologia , Jogo de Azar/tratamento farmacológico , Jogo de Azar/fisiopatologia , Jogo de Azar/psicologia , Humanos , Internet , Comportamento Sexual/efeitos dos fármacos , Transtornos Relacionados ao Uso de Substâncias/diagnóstico , Transtornos Relacionados ao Uso de Substâncias/fisiopatologia , Transtornos Relacionados ao Uso de Substâncias/psicologia , Resultado do TratamentoRESUMO
This chapter focuses on psychotherapy of substance and non-substance addiction (see Cognitive Behavioral Therapy in Chap. 16 ) and introduces the latest advances, mainly in the mindfulness-based relapse prevention, PITDH, and points out that complete elimination of psychological addiction is hopefully to become the target and core of the psychotherapy of addiction disorder. This chapter also introduces methods and progress of various types of substance and non-substance addiction.
Assuntos
Comportamento Aditivo/terapia , Encéfalo/fisiopatologia , Usuários de Drogas/psicologia , Psicoterapia/métodos , Transtornos Relacionados ao Uso de Substâncias/terapia , Alcoolismo/fisiopatologia , Alcoolismo/psicologia , Alcoolismo/terapia , Atitude Frente aos Computadores , Comportamento Aditivo/diagnóstico , Comportamento Aditivo/fisiopatologia , Comportamento Aditivo/psicologia , Dependência de Alimentos/fisiopatologia , Dependência de Alimentos/psicologia , Dependência de Alimentos/terapia , Jogo de Azar/fisiopatologia , Jogo de Azar/psicologia , Jogo de Azar/terapia , Humanos , Internet , Recidiva , Comportamento Sexual , Transtornos Relacionados ao Uso de Substâncias/diagnóstico , Transtornos Relacionados ao Uso de Substâncias/fisiopatologia , Transtornos Relacionados ao Uso de Substâncias/psicologia , Resultado do TratamentoRESUMO
Cognitive-behavioral therapy (CBT) is the main method of psychotherapy generally accepted in the field of substance addiction and non-substance addiction. This chapter mainly introduces the methods and technology of cognitive-behavior therapy of substance addiction, especially in order to prevent relapse. In the cognitive-behavior treatment of non-substance addiction, this chapter mainly introduces gambling addiction and food addiction.
Assuntos
Comportamento Aditivo/terapia , Encéfalo/fisiopatologia , Terapia Cognitivo-Comportamental , Usuários de Drogas/psicologia , Transtornos Relacionados ao Uso de Substâncias/terapia , Comportamento Aditivo/diagnóstico , Comportamento Aditivo/fisiopatologia , Comportamento Aditivo/psicologia , Dependência de Alimentos/fisiopatologia , Dependência de Alimentos/psicologia , Dependência de Alimentos/terapia , Jogo de Azar/fisiopatologia , Jogo de Azar/psicologia , Jogo de Azar/terapia , Humanos , Recidiva , Transtornos Relacionados ao Uso de Substâncias/diagnóstico , Transtornos Relacionados ao Uso de Substâncias/fisiopatologia , Transtornos Relacionados ao Uso de Substâncias/psicologia , Resultado do TratamentoRESUMO
PURPOSE: During clinical monitoring, vecuronium appeared to reduce the rapidly extracted auditory evoked potentials index (A-line ARX index or AAI) to some extent. A prospective and randomized study was designed to analyze this phenomenon. METHODS: Forty adult patients undergoing elective surgery were studied. After tracheal intubation, anesthesia was maintained with an end-tidal isoflurane concentration (F(ET)ISO) of 1.0% for 20 min, then a 10-mL dose of either vecuronium 0.05 mg*kg(-1), 0.1 mg*kg(-1), 0.2 mg*kg(-1) or saline was administered in a randomized, double-blind design. The AAI and bispectral index (BI(hx)) were monitored throughout the study and analyzed off-line. RESULTS: BI(hx) was unaltered after the administration of saline or vecuronium. The mean of the averaged (per patient) AAI values recorded from two minutes to ten minutes after the administration of saline or vecuronium 0.05 mg*kg(-1) did not differ significantly from the corresponding mean recorded from 15 min to 20 min after F(ET)ISO maintained 1.0% (P = 0.678, 0.169), however after the administration of vecuronium 0.1 mg*kg(-1) or 0.2 mg*kg(-1), AAI was reduced from 18.3, 18.0 to 14.8, 13.4 (P = 0.016, 0.017). CONCLUSIONS: Neuromuscular block with vecuronium reduces AAI in patients during steady state anesthesia without surgical stimuli, while BI(hx) is unaltered. The cut-off values of AAI for events should be determined according to the level of neuromuscular blockade when monitoring the depth of anesthesia/sedation.